Momentum builds for female sexual dysfunction Tx

This content was generated via a Google Alert and the content is owned by the original site

Click here to visit the original site

A number of prominent urologists are among the signers of a letter applauding the FDA for holding a workshop on female sexual dysfunction.

More than 80 experts in male sexual dysfunction—including several U.S. urologists in clinical and academic practice—signed the letter praising the organization’s decision to hold a 2-day workshop in late October focusing on female sexual dysfunction, a condition the FDA has designated a priority unmet medical need.

“As clinicians, we see on a daily basis the impact that sexual dysfunction has on the affected woman as well as her partner. We have seen, over the years, the benefits to women of treating their sexually dysfunctional male partners and we expect that treating the similarly affected woman will enhance not just her life but that of the couple,” reads the letter, whose signers are led by John P. Mulhall, MD, of Memorial Sloan Kettering Cancer Center, New York.

To date, the FDA has approved 26 different drugs that are marketed for the treatment of male sexual dysfunction (erectile dysfunction and low testosterone) and none for the treatment of women’s most common sexual health complaint, hypoactive sexual desire disorder, according to a statement from advocacy group Even the Score.

Even the Score called the Oct. 27-28 workshop “a historic moment in the fight for gender equity in sexual health where patients, patient advocates, health care providers, and sexual health experts will discuss the issue and the need for medical treatment options for women.”



Other recent Urology Times articles

Number of sexual partners linked to PCa risk

Diet and male fertility: What helps, what hurts

Vitamin D, prostate Ca: Study points to missing link


Comments are closed.